Differential Expression of Metastasis-Associated Genes in Papilla of Vater and Pancreatic Cancer Correlates With Disease Stage
- 1 May 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (9), 2422-2432
- https://doi.org/10.1200/jco.2001.19.9.2422
Abstract
PURPOSE: Papilla of Vater cancer has a much better prognosis than pancreatic cancer. It is not known whether this is the result of differences in the tumor biology of the two malignancies. Because metastasis formation is a critical step in tumor progression and a negative prognostic factor, we compared the expression of nm23-H1 and KAI1, two metastasis-suppressing genes, in papilla of Vater cancer and pancreatic cancer. PATIENTS AND METHODS: Analysis was performed in nine normal human papilla of Vater samples, 27 papilla of Vater cancers, 16 normal pancreatic samples, and 29 pancreatic cancers. Expression of nm23-H1 and KAI1 was analyzed by Northern blot analysis and in situ hybridization. In addition, immunohistochemistry was performed to localize the respective proteins. RESULTS: There was no difference in nm23-H1 and KAI1 mRNA expression levels in normal versus cancerous papilla of Vater samples. In contrast, nm23-H1 and KAI1 RNA expression was upregulated in early tumor stages of pancreatic cancer and reduced in advanced tumor stages. When expression of nm23-H1 and KAI1 RNA was analyzed by use of in situ hybridization, normal epithelial cells of the papilla of Vater exhibited mRNA staining intensity similar to that of papilla of Vater cancer cells. Similar levels of nm23-H1 and KAI1 immunoreactivity also were observed in these samples. In contrast, early stage pancreatic cancer samples exhibited stronger nm23-H1 and KAI1 immunoreactivity than normal controls. Furthermore, early pancreatic cancer stages exhibited higher KAI1 and nm23-H1 immunostaining than advanced tumor stages. CONCLUSION: Differences in the expression patterns of the two tumor suppressor genes nm23-H1 and KAI1 may contribute to the different prognoses of papilla of Vater cancer and pancreatic cancer. Our findings support the hypothesis that biologic differences rather than earlier diagnosis influence the different outcomes of these two tumor entities.This publication has 34 references indexed in Scilit:
- KAI1, A new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinomaJournal of Hepatology, 1998
- Nm23‐H1 expression in intrahepatic or extrahepatic metastases of hepatocellular carcinomaLiver International, 1998
- Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 geneOncogene, 1998
- Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancerInternational Journal of Cancer, 1995
- KAI1 , a Metastasis Suppressor Gene for Prostate Cancer on Human Chromosome 11p11.2Science, 1995
- Surgical Treatment of Pancreatic CancerDigestive Surgery, 1994
- Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.JCI Insight, 1992
- Expression in Human Hepatocellular Carcinoma of Nucleoside Diphosphate Kinase, a Homologue of the nm23 Gene ProductJNCI Journal of the National Cancer Institute, 1992
- Pancreatic CarcinomaThe New England Journal of Medicine, 1992
- Biological Diversity in Metastatic Neoplasms: Origins and ImplicationsScience, 1982